Literature DB >> 11558988

Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report.

C P Bleeker1, R C Bremer, D A Dongelmans, R T van Dongen, B J Crul.   

Abstract

Pain partially responsive to opioids can lead to rapid escalating dosages due to tolerance development. In this report the case of a 58-year-old female with neuropathic pain using increasing transdermal (TTS) fentanyl dosages to a maximum dose of 3400 microg/h resulting in fentanyl plasma levels of 173 ng/ml is described. For pain relief an epidural infusion at the level T1-2 with bupivacaine was started. Immediate pain relief was accompanied by short lasting respiratory depression and drowsiness. Copyright 2001 European Federation of Chapters of the International Association for the study of Pain.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11558988     DOI： 10.1053/eujp.2000.0220

Source DB:  PubMed          Journal:  Eur J Pain        ISSN： 1090-3801            Impact factor:   3.931


  8 in total

Review 1.  Bioequivalence criteria for transdermal fentanyl generics: do these need a relook?

Authors:  Carmen Walter; Lisa Felden; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

2.  Comparing fatal cases involving U-47700.

Authors:  Xiulu Ruan; Srinivas Chiravuri; Alan D Kaye
Journal:  Forensic Sci Med Pathol       Date:  2016-07-16       Impact factor: 2.007

3.  Toxicological testing when evaluating fatal cases suspected of acute fentanyl toxicity.

Authors:  Xiulu Ruan; Srinivas Chiravuri; Alan D Kaye
Journal:  Forensic Sci Med Pathol       Date:  2016-07-07       Impact factor: 2.007

4.  High-dose fentanyl patch for cancer pain of a patient with cholangiocarcinoma.

Authors:  Jung Han Kim; Mi Kim; Chong Won Sung; Hyeoung Su Kim; Hyun Joo Jang; Young Chul Shin; Joo Young Jung
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 2.884

5.  The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation.

Authors:  M Petraschka; S Li; T L Gilbert; R E Westenbroek; M R Bruchas; S Schreiber; J Lowe; M J Low; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-04-30       Impact factor: 3.590

6.  Analgesic effect of piracetam on peripheral neuropathic pain induced by chronic constriction injury of sciatic nerve in rats.

Authors:  Ashish K Mehta; Yogendra Bhati; Chakra D Tripathi; Krishna K Sharma
Journal:  Neurochem Res       Date:  2014-05-16       Impact factor: 3.996

7.  Increased methylation of the MOR gene proximal promoter in primary sensory neurons plays a crucial role in the decreased analgesic effect of opioids in neuropathic pain.

Authors:  Xue-Long Zhou; Li-Na Yu; Yin Wang; Li-Hui Tang; Yu-Nan Peng; Jun-Li Cao; Min Yan
Journal:  Mol Pain       Date:  2014-08-13       Impact factor: 3.395

Review 8.  Targeting Chemokines and Chemokine GPCRs to Enhance Strong Opioid Efficacy in Neuropathic Pain.

Authors:  Martina Vincenzi; Michele Stanislaw Milella; Ginevra D'Ottavio; Daniele Caprioli; Ingrid Reverte; Daniela Maftei
Journal:  Life (Basel)       Date:  2022-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.